DK3549949T3 - Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil - Google Patents

Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil Download PDF

Info

Publication number
DK3549949T3
DK3549949T3 DK19167276.5T DK19167276T DK3549949T3 DK 3549949 T3 DK3549949 T3 DK 3549949T3 DK 19167276 T DK19167276 T DK 19167276T DK 3549949 T3 DK3549949 T3 DK 3549949T3
Authority
DK
Denmark
Prior art keywords
methods
clostridium difficile
difficile toxin
compositions relating
mutant clostridium
Prior art date
Application number
DK19167276.5T
Other languages
English (en)
Other versions
DK3549949T5 (da
Inventor
Maninder K Sidhu
Annaliesa Sybil Anderson
Robert G K Donald
Kathrin Ute Jansen
Narender K Kalyan
Terri L Mininni
Justin Keith Moran
Mark E Ruppen
Michael James Flint
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of DK3549949T3 publication Critical patent/DK3549949T3/da
Application granted granted Critical
Publication of DK3549949T5 publication Critical patent/DK3549949T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19167276.5T 2011-04-22 2012-04-20 Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil DK3549949T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US201161478899P 2011-04-25 2011-04-25
EP12720966.6A EP2699587B1 (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Publications (2)

Publication Number Publication Date
DK3549949T3 true DK3549949T3 (da) 2023-12-18
DK3549949T5 DK3549949T5 (da) 2024-09-02

Family

ID=46085103

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19167276.5T DK3549949T5 (da) 2011-04-22 2012-04-20 Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
DK12720966.6T DK2699587T3 (da) 2011-04-22 2012-04-20 Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12720966.6T DK2699587T3 (da) 2011-04-22 2012-04-20 Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil

Country Status (29)

Country Link
US (13) US8481692B2 (da)
EP (4) EP3505531B1 (da)
JP (8) JP5917682B2 (da)
KR (1) KR101667837B1 (da)
CN (3) CN107022532B (da)
AR (1) AR086199A1 (da)
AU (6) AU2012245904B2 (da)
BR (2) BR112013027229B1 (da)
CA (1) CA2832712C (da)
CO (1) CO6801643A2 (da)
DK (2) DK3549949T5 (da)
ES (3) ES2968629T3 (da)
FI (1) FI3549949T3 (da)
HR (2) HRP20231631T1 (da)
HU (2) HUE047085T2 (da)
IL (8) IL270779B2 (da)
MX (1) MX347521B (da)
MY (2) MY168205A (da)
NZ (1) NZ616035A (da)
PE (2) PE20141029A1 (da)
PL (3) PL3505531T3 (da)
PT (2) PT2699587T (da)
RU (2) RU2754446C2 (da)
SA (3) SA112330472B1 (da)
SG (3) SG10201602668VA (da)
SI (3) SI3549949T1 (da)
TW (6) TWI671313B (da)
WO (1) WO2012143902A1 (da)
ZA (1) ZA201307818B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
PE20110998A1 (es) * 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014072277A1 (de) * 2012-11-06 2014-05-15 Bayer Pharma Aktiengesellschaft Formulierung für bispecific t-cell-engangers (bites)
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CA2915279A1 (en) 2013-06-14 2014-12-18 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
EP3256855B1 (en) * 2015-02-13 2020-10-07 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
WO2019064115A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
EP3946444A1 (en) 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US20220313809A1 (en) * 2019-05-10 2022-10-06 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile tcdb variants, vaccines and methods of use
US20220226430A1 (en) * 2019-05-11 2022-07-21 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021226330A1 (en) * 2020-05-06 2021-11-11 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
US20230218735A1 (en) 2020-06-19 2023-07-13 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024127215A2 (en) 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
AU668092B2 (en) 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
DE69432665T3 (de) 1993-03-29 2007-12-06 Pfizer Inc. Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt
JPH10505358A (ja) 1994-09-06 1998-05-26 ギャラゲン・インコーポレイテッド クロストリジウム・ディフィシル関連疾患の治療処置
EP1041149B8 (en) 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
WO1997002835A1 (en) 1995-07-07 1997-01-30 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
CA2232001C (en) * 1995-09-15 2002-12-10 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
CA2260836A1 (en) 1996-07-12 1998-01-22 Edwin C. Iliff Computerized medical diagnostic system utilizing list-based processing
DE69730152T2 (de) 1996-09-30 2005-11-03 University Of Arkansas, Fayetteville Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
IL152553A0 (en) * 2000-05-04 2003-05-29 Harvard College Compounds and methods for the treatment and prevention of bacterial infection
ATE349468T1 (de) * 2001-06-20 2007-01-15 Univ Ramot Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE602004010376T2 (de) * 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
ES2707786T3 (es) 2004-01-16 2019-04-05 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
DK2270045T3 (da) 2004-02-06 2015-04-07 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelser deraf
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
WO2007126816A2 (en) * 2006-03-30 2007-11-08 Embrex, Inc. Methods and compositions for vaccination of poultry
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CN101617362B (zh) * 2007-03-02 2012-07-18 松下电器产业株式会社 语音解码装置和语音解码方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CA2699435A1 (en) * 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
EP2288719A4 (en) 2008-05-15 2012-01-11 Univ Tufts DIFFICULT CLOSTRIDIUM DIAGNOSTIC METHODS AND METHODS AND VECTORS FOR EXPRESSION OF RECOMBINANT TOXINS
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
US20120020996A1 (en) 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
EP3067426A3 (en) 2008-09-24 2016-12-07 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
CN102264381B (zh) 2008-10-01 2014-07-09 美国政府(由卫生和人类服务部的部长所代表) 提供对疟原虫的长效免疫应答的用于疟疾的多组分疫苗
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010063693A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体
JP2013503198A (ja) * 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JP2013512916A (ja) * 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
NZ602958A (en) 2010-03-30 2014-07-25 Pfenex Inc High level expression of recombinant toxin proteins
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
LT2753352T (lt) * 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2638063A4 (en) * 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc GB 1 PEPTIDE BANKS AND ASSOCIATED COMPOUNDS, AND SCREENING METHODS THEREOF
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
ES2743442T3 (es) 2011-05-27 2020-02-19 Glaxosmithkline Biologicals Sa Composición inmunogénica
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
RU2014127714A (ru) * 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
WO2014045226A1 (en) 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013352034B2 (en) 2012-11-28 2018-08-02 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
EP3513806B1 (en) 2012-12-05 2023-01-25 GlaxoSmithKline Biologicals SA Immunogenic composition
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014144567A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
CA2915279A1 (en) 2013-06-14 2014-12-18 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
WO2015061529A1 (en) 2013-10-23 2015-04-30 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2016357567B2 (en) 2015-11-17 2020-05-07 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
CN117244049A (zh) 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法
KR102640722B1 (ko) 2017-03-15 2024-02-26 노바백스, 인코포레이티드 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
WO2019064115A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
JP2018052938A (ja) 2018-04-05
CN107022532A (zh) 2017-08-08
JP2018135345A (ja) 2018-08-30
AU2012245904A1 (en) 2013-10-17
US10774117B2 (en) 2020-09-15
US20130244307A1 (en) 2013-09-19
IL270779A (en) 2020-01-30
US10597428B2 (en) 2020-03-24
US20200095290A1 (en) 2020-03-26
EP4365196A2 (en) 2024-05-08
HUE065594T2 (hu) 2024-06-28
IL273231A (en) 2020-04-30
ZA201307818B (en) 2014-06-25
IL273231B (en) 2021-08-31
IL265510B (en) 2021-05-31
SG10201602668VA (en) 2016-05-30
HUE047085T2 (hu) 2020-04-28
MX347521B (es) 2017-04-27
USRE46376E1 (en) 2017-04-25
PL2699587T3 (pl) 2019-12-31
US8481692B2 (en) 2013-07-09
HRP20240042T1 (hr) 2024-03-29
EP2699587B1 (en) 2019-07-03
MY168205A (en) 2018-10-15
PT2699587T (pt) 2019-09-05
AU2017261465B2 (en) 2018-10-04
TWI671313B (zh) 2019-09-11
JP6892425B2 (ja) 2021-06-23
SA115360698B1 (ar) 2016-04-27
PE20181334A1 (es) 2018-08-21
RU2592686C2 (ru) 2016-07-27
JP7097478B2 (ja) 2022-07-07
TW201806967A (zh) 2018-03-01
ES2742823T3 (es) 2020-02-17
DK2699587T3 (da) 2019-08-05
TWI815599B (zh) 2023-09-11
TW202041525A (zh) 2020-11-16
IL265510A (en) 2019-05-30
EP3505531B1 (en) 2023-11-15
TW201932481A (zh) 2019-08-16
JP6735784B2 (ja) 2020-08-05
USRE46518E1 (en) 2017-08-22
CN107022532B (zh) 2021-05-04
CN111647059A (zh) 2020-09-11
SG194132A1 (en) 2013-11-29
US8900597B2 (en) 2014-12-02
US20130330371A1 (en) 2013-12-12
NZ616035A (en) 2016-03-31
EP3505531A1 (en) 2019-07-03
CA2832712A1 (en) 2012-10-26
JP2017125030A (ja) 2017-07-20
AU2018201296A1 (en) 2018-03-15
MY182429A (en) 2021-01-25
TWI804717B (zh) 2023-06-11
FI3549949T3 (fi) 2024-01-30
IL254440B (en) 2019-12-31
AR086199A1 (es) 2013-11-27
TW201302780A (zh) 2013-01-16
CN103619871A (zh) 2014-03-05
BR122019017005B1 (pt) 2022-03-29
JP6097853B2 (ja) 2017-03-15
HRP20231631T1 (hr) 2024-03-15
IL255345A0 (en) 2017-12-31
IL228944A (en) 2017-11-30
US20150125927A1 (en) 2015-05-07
RU2013145170A (ru) 2015-06-27
US20230391835A1 (en) 2023-12-07
IL270779B2 (en) 2024-09-01
BR112013027229B1 (pt) 2020-10-27
JP2019052149A (ja) 2019-04-04
AU2019246878B2 (en) 2020-09-10
AU2016202903A1 (en) 2016-05-26
IL228944A0 (en) 2013-12-31
KR101667837B1 (ko) 2016-10-20
JP5917682B2 (ja) 2016-05-18
TWI701257B (zh) 2020-08-11
JP2014514318A (ja) 2014-06-19
EP4365196A3 (en) 2024-08-07
ES2968629T3 (es) 2024-05-13
BR112013027229A2 (pt) 2016-11-29
JP2021130692A (ja) 2021-09-09
US11535652B2 (en) 2022-12-27
SI3505531T1 (sl) 2024-02-29
AU2012245904B2 (en) 2016-04-21
RU2015154443A (ru) 2019-01-17
US8557548B2 (en) 2013-10-15
USRE48863E1 (en) 2021-12-28
JP2022126822A (ja) 2022-08-30
IL254418A0 (en) 2017-11-30
DK3549949T5 (da) 2024-09-02
AU2019246878A1 (en) 2019-10-31
IL255345B (en) 2021-05-31
IL245047A0 (en) 2016-05-31
RU2015154443A3 (da) 2019-05-22
US20150307563A1 (en) 2015-10-29
SA115360697B1 (ar) 2016-04-05
CO6801643A2 (es) 2013-11-29
USRE48862E1 (en) 2021-12-28
CN111647059B (zh) 2023-11-28
US20120269841A1 (en) 2012-10-25
CN103619871B (zh) 2016-12-14
US9745354B2 (en) 2017-08-29
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
PL3505531T3 (pl) 2024-03-11
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
WO2012143902A1 (en) 2012-10-26
TW201932480A (zh) 2019-08-16
KR20130140206A (ko) 2013-12-23
JP2016117745A (ja) 2016-06-30
JP6321239B2 (ja) 2018-05-09
CA2832712C (en) 2018-08-28
PE20141029A1 (es) 2014-09-04
PL3549949T3 (pl) 2024-04-08
RU2754446C2 (ru) 2021-09-02
PT3549949T (pt) 2024-02-02
MX2013012344A (es) 2013-11-20
EP3549949B1 (en) 2023-11-29
SI2699587T1 (sl) 2019-08-30
SA112330472B1 (ar) 2015-11-02
IL254418B (en) 2019-12-31
AU2016202903B2 (en) 2017-11-30
AU2017261465A1 (en) 2017-11-30
US20190202873A1 (en) 2019-07-04
TW202320843A (zh) 2023-06-01
EP2699587A1 (en) 2014-02-26
AU2020230248A1 (en) 2020-10-01
AU2020230248B2 (en) 2022-12-01
US20170313749A1 (en) 2017-11-02
ES2969952T3 (es) 2024-05-23
SG10201911993UA (en) 2020-02-27
US9187536B1 (en) 2015-11-17
EP3549949A1 (en) 2019-10-09
TWI650329B (zh) 2019-02-11

Similar Documents

Publication Publication Date Title
IL273231B (en) Clostridium difficile toxin-related preparations and methods
IL284582A (en) Compositions and methods related to mutant Clostridium difficile toxin
EP2744517A4 (en) COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL ANTI-PROTEIN ANTIBODIES
BR112013032426A2 (pt) composições probióticas e métodos
DK2758432T3 (da) Neutraliserende antistoffer mod hovedtoksinerne TcdA og TcdB fra Clostridium difficile
EP2776829A4 (en) METHODS AND USES OF METABOLIC PROFILING FOR DIFFICULT CLOSTRIDIUM INFECTION (CDI)
EP2841593A4 (en) CLOSTRIDIUM DIFFICILE DEHYDROGENASE AND TOXIN AS A BIOMARKER
DK2633029T3 (da) Sammensætninger og fremgangsmåder til dyrkning af spirokæter